TRCT
TNXP icon

Tower Research Capital (TRC)’s Tonix Pharmaceuticals TNXP Stock Holding History

Tower Research Capital (TRC)’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2K Sell
1,178
-247
-17% -$3.8K ﹤0.01% 3626
2025
Q4 		$22.3K Sell
1,425
-2,034
-59% -$37.5K ﹤0.01% 3017
2025
Q3 		$83.6K Sell
3,459
-3,713
-52% -$138K ﹤0.01% 2144
2025
Q2 		$258K Buy
7,172
+3,731
+108% +$97.8K 0.01% 1554
2025
Q1 		$61.5K Buy
+3,441
New +$69.8K ﹤0.01% 2083
2024
Q4 		– Sell
-356
Closed -$5.3K – 6005
2024
Q3 		$5.3K Buy
356
+306
+612% +$12.3K ﹤0.01% 4293
2024
Q2 		$3.51K Buy
50
+39
+355% +$17.7K ﹤0.01% 4879
2024
Q1 		$6.4K Buy
+11
New +$11.8K ﹤0.01% 4378
2022
Q4 		– Sell
-1
Closed -$6K – 6378
2022
Q3 		$6K Buy
+1
New +$24.5K ﹤0.01% 5058
2022
Q2 		– Hold
0
– – – 4313
2022
Q1 		– Hold
0
– – – 3647
2021
Q4 		– Hold
0
– – – 4611
2021
Q3 		– Hold
0
– – – 4675
2021
Q2 		– Hold
0
– – – 3611
2021
Q1 		– Hold
0
– – – 4435
2019
Q2 		– Hold
0
– – – 4294
2019
Q1 		– Hold
0
– – – 4274
2017
Q2 		– Hold
0
– -$11K – 3442
2017
Q1 		– Hold
0
– – – 1718
2016
Q3 		– Hold
0
– -$1K – 4443
2016
Q2 		– Hold
0
– – – 4218
2016
Q1 		– Hold
0
– – – 2410
2015
Q3 		– Hold
0
– -$3K – 4763
2015
Q2 		– Hold
0
– – – 3585
2015
Q1 		– Hold
0
– – – 3826
2014
Q4 		– Hold
0
– – – 3160
2014
Q3 		– Hold
0
– – – 4157
2014
Q2 		– Hold
0
– – – 3759
2014
Q1 		– Hold
0
– – – 3912
2013
Q4 		– Hold
0
– – – 2686
2013
Q3 		– Hold
0
– – – 3971

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Tower Research Capital (TRC)'s TNXP Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Tonix Pharmaceuticals (TNXP) stake by 17% in Q1 2026, selling an estimated $3.8K and leaving 1,178 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3626.

Tower Research Capital (TRC) first reported a position in TNXP in Q3 2022 and has held it in 9 quarters since. The position peaked at $258K in Q2 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Tower Research Capital (TRC) held 1,178 shares of Tonix Pharmaceuticals worth $16.2K as of Q1 2026.
  • Tower Research Capital (TRC) sold 247 Tonix Pharmaceuticals shares in Q1 2026, an estimated $3.8K.
  • Tonix Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3626 holding.
  • Tower Research Capital (TRC) first reported a position in Tonix Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Tonix Pharmaceuticals position peaked at $258K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.